Is abortion covered by Medicare in Australia?

Partial Medicare coverage exists. Consultations with a GP or specialist for reproductive health attract a Medicare rebate, and certain surgical procedures attract a rebate, but the gap between the schedule fee and what practitioners actually charge means significant out-of-pocket costs remain for many patients. Medical abortion medications (mifepristone and misoprostol) are on the PBS but require a prescription from an authorised prescriber. Access varies significantly by location — rural and regional areas have fewer providers.

What is the SPHERE Coalition?

SPHERE is an NHMRC-funded centre for research excellence led by Monash University, focused on sexual and reproductive health access for women in the general practice setting. It brings together medical researchers, clinicians, consumer advocates, and peak body representatives to generate and translate evidence on reproductive health access and outcomes.

Nine steps to close Australia's abortion care equity gap

What just happened

The SPHERE Coalition — a National Health and Medical Research Council–funded research centre led by Monash University — published a nine-recommendation roadmap on Thursday aimed at closing what it describes as Australia’s abortion care equity gap. The recommendations target the affordability and geographic barriers that leave reproductive healthcare inaccessible for a significant proportion of women.

The report’s nine recommendations:

A targeted bulk-billing incentive for sexual and reproductive health GP consultations
Funded no-cost ultrasound services (currently an out-of-pocket cost for many patients)
Improved Medicare rebates for surgical abortion
Subsidised abortion medications and consumables
Reformed health insurance arrangements for temporary visa holders
State and territory navigation services to help patients find and access care
Funded intrauterine contraception device insertion during surgical abortion
Removal of mandatory counselling requirements that delay access in some jurisdictions
Expanded prescriber authorisation for medical abortion

The roadmap follows the 2023 Senate Inquiry into Universal Access to Reproductive Healthcare, which found substantial equity gaps across income, geography, and visa status. No legislative changes have been introduced in response to either document at this stage.

The both-and

What the equity gap actually looks like

SPHERE Chair Professor Danielle Mazza used the word “critical” to describe the affordability problem. That framing is supported by what the costs actually add up to for patients navigating the existing system.

A woman accessing surgical abortion in the private sector faces a GP consultation fee, a referral, a specialist consultation, anaesthesia, a facility fee, and, separately, a pre-procedure ultrasound. The Medicare rebate applies at each step — but the gap between the schedule fee and the actual charge is a separate cost at every point. In the public hospital system, surgical abortion is available in most states, but wait times can be long and gestational limits apply. The practical result is that women who can pay privately move through the system faster, and women who cannot pay are funnelled into a public system under time pressure.

For medical abortion (the combination of mifepristone and misoprostol taken orally at home), access is structured differently. The drugs are on the Pharmaceutical Benefits Scheme, which means they are subsidised for eligible patients. But only authorised prescribers can write the prescription — GPs must complete additional training and registration to prescribe, and not all GPs have done so. Rural patients may not have an authorised prescriber within their region, meaning medical abortion requires either travel or telehealth access, both of which have their own logistical barriers.

The geographic dimension compounds the affordability one. In metropolitan areas, multiple clinic options exist. In outer regional and remote Australia, the nearest provider may be hundreds of kilometres away. The SPHERE recommendations that address this — navigation services, expanded prescriber authorisation — speak directly to the geography problem.

What the roadmap doesn’t resolve

The recommendations are well-targeted at structural access barriers, but they engage primarily with the Medicare and system design level. Some of the most persistent barriers to abortion access operate at a different level.

Provider availability in rural areas is not purely a financial problem. It reflects a shortage of practitioners willing or able to provide the service, intersecting with conscientious objection provisions that exist in most jurisdictions (allowing individual practitioners to decline to refer or provide, with varying obligations to ensure alternative access). The roadmap does not address this directly — conscientious objection provisions are matters for state and territory health legislation, not Medicare.

The push to expand authorised prescriber status for medical abortion is among the recommendations with the most near-term potential reach. Australia increased access to medical abortion significantly in 2023 when telehealth prescribing was enabled for authorised GPs — a change that allowed women to complete a medication course without physically attending a clinic. Expanding the prescriber base would extend that further. The limiting factor has been GP training and registration, not the existence of the telehealth mechanism.

The both-and here is familiar in health policy: evidence-based system recommendations identify where the levers are, but moving them requires political will and funding commitments that the roadmap itself cannot supply. The Senate inquiry of 2023 identified similar structural problems. The question of what the present government will do in response to this roadmap is separate from whether the roadmap’s analysis is sound — and it is.

My two cents

If you are navigating reproductive healthcare access and are uncertain what is available to you, a general practice consultation is the most direct starting point. Your GP can clarify what local providers exist, whether you are within reach of an authorised medical abortion prescriber, and how to navigate the public hospital pathway if that is more appropriate for your situation.

If you are in a regional or rural area and are uncertain about nearest providers, the Tabbot Foundation telehealth service provides authorised medical abortion consultations for eligible patients across most of Australia — it is not the only telehealth option, but it is an accessible reference point.

The SPHERE roadmap is a research-based document from a credible clinical coalition. It does not have the force of law, and the policy landscape it describes has not changed as of today. What it signals is where the clinical and research community thinks the system gaps are. Whether those gaps close will depend on what happens next in the federal budget process and at state and territory level.

Verdict: yes — worth knowing about.

Sources cited

“Experts unveil roadmap to close abortion care equity gap” — RACGP NewsGP, 28 August 2026. https://www1.racgp.org.au/newsgp/clinical/experts-unveil-roadmap-to-close-abortion-care-equi
SPHERE — National NHMRC Centre of Research Excellence, Monash University. https://www.monash.edu/medicine/sphere
Senate Inquiry into Universal Access to Reproductive Healthcare, 2023. https://www.aph.gov.au/Parliamentary_Business/Committees/Senate/Community_Affairs/ReproductiveHealthcare